SHANGHAI, Nov. 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced today that it has ...
Building on its success in developing continuous production at pilot-scale with the WuXiUP platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance ...
Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback